1. Home
  2. NABL vs STTK Comparison

NABL vs STTK Comparison

Compare NABL & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo N-able Inc.

NABL

N-able Inc.

HOLD

Current Price

$4.14

Market Cap

761.3M

Sector

Technology

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.58

Market Cap

792.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NABL
STTK
Founded
2000
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
761.3M
792.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
NABL
STTK
Price
$4.14
$6.58
Analyst Decision
Buy
Buy
Analyst Count
5
7
Target Price
$8.31
★ $10.00
AVG Volume (30 Days)
★ 2.3M
861.2K
Earning Date
05-07-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 53.02
EPS
★ N/A
N/A
Revenue
★ $511,430,000.00
$1,000,000.00
Revenue This Year
$11.04
N/A
Revenue Next Year
$8.53
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 9.71
N/A
52 Week Low
$2.92
$1.70
52 Week High
$8.74
$8.33

Technical Indicators

Market Signals
Indicator
NABL
STTK
Relative Strength Index (RSI) 52.79 48.80
Support Level $3.81 $5.85
Resistance Level $4.24 $7.75
Average True Range (ATR) 0.21 0.34
MACD 0.01 0.05
Stochastic Oscillator 69.07 83.13

Price Performance

Historical Comparison
NABL
STTK

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: